Plain-English translation of NCT05540288 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a medication that works on the brain's reward system, to see if it can help reduce cravings in people with behavioral addictions like gambling disorder, food addiction, or sexual addiction. Cravings—those overwhelming urges to engage in addictive behaviors—are a major reason why people struggle to stay in control and often relapse. This study will compare the medication to a placebo (an inactive pill) to see if truly helps when added to the treatment people are already receiving.
Currently, there is no FDA-approved medication specifically for behavioral addictions, even though they affect millions of people and can cause serious harm. The medication being tested has shown promise in earlier studies for gambling disorder, but it has never been studied for food or sexual addiction. This trial aims to fill that gap by testing whether this treatment can work across multiple types of behavioral addiction.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the medication (36 mg daily) or a placebo pill, both taken in addition to your regular addiction treatment. You will need to keep a weekly diary to report your craving episodes and their intensity, and you'll have regular visits with the research team to monitor your progress. The study is designed to track how the medication affects your cravings over time compared to the placebo group.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
France